Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • Nyxol
    • APX3330
    • APX2009
    • Posters and Publications
  • Clinical Trials
    • Overview
    • VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia Enrolling
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Last Patient Last Visit Completed
    • MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Completed
    • MIRA-3 Completed
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Completed
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Completed
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

For more details, click here for the full news release.

Continue

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 9, 2021

Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints

Jun 30, 2021

Processa Pharmaceuticals Enters Into A Licensing Agreement With Ocuphire Pharma, Inc., For The Development Of RX-3117

Jun 17, 2021

Ocuphire Announces Addition to the Russell Microcap® Index

Jun 11, 2021

Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market

Jun 8, 2021

Ocuphire Announces Appointment of Jay S. Pepose, M.D., Ph.D. to Its Board of Directors

Jun 8, 2021

Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 4, 2021

Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis

May 20, 2021

Ocuphire Granted Two New U.S. Patents Covering Late-Stage Drug Candidate Nyxol®, Including for the Treatment of Presbyopia

May 18, 2021

Ocuphire Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol® in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia

May 12, 2021
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...40
    Ocuphire Pharma, Inc.
    © Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use